The promise of next-generation flow cytometry platforms including mass cytometry (CyTOF) and mass spectrometry-based digital imaging is substantial. With widespread use in immunophenotyping, analysis of hematopoietic neoplasias, diagnosis of primary immunodeficiencies, and for antibody screening and crossmatching, among other applications, flow cytometry is expected to continue to expand its clinical utility and utilization in clinical laboratories.
Utilization of flow cytometry has remained quite consistent over the past 5 years with just under 2 out of every 10 facilities taking advantage of this technology.
While its use in smaller facilities (<200 beds) is relatively scant, flow cytometry is commonly utilized in the largest facilities (400+ beds).
Flow cytometry instrumentation delivers strong satisfaction, with 91% rating their vendors as excellent or good.
While most new adoptions will be concentrated in 400+ bed facilities, midsized hospitals expect to enjoy increasing adoption rates in the coming years.
Enter our Sweepstakes now for your chance to win the following prizes:
Just answer the following quick question for your chance to win:
Entries are limited to one entry per person in any active sweepstakes.
Thank you for your entry.